Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PT on Tuesday, January 8, 2008. The conference is being held at the Westin St. Francis Hotel in San Francisco, California.

Daniel B. Carr M.D., Javelin's CEO/CMO, will provide an overview of the company, discuss Javelin's business, as well as recent developments, and outline future opportunities. Javelin's presentation will be webcast live for investors and available for replay for a period of three months following the conference. The presentation can be accessed by logging onto the Investor Relations section at the Company's web site at http://www.javelinpharma.com. Those wishing to hear the presentation live should log on approximately five minutes prior to its start.

"We are very pleased to present at the JPMorgan Healthcare Conference, where we are also hosting the largest number of investor, analyst, and prospective partnering meetings Javelin has ever had at any healthcare conference," said Dr. Carr. "Further, all of us at Javelin were delighted to be identified as one of the two top emerging small cap specialty pharmaceutical stocks for 2008 in a recent JPMorgan research report by Adam Greene," said Dr. Carr.

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.

Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.